synthego ipo
Synthego is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms at scale. For instance, Synthego Corporation introduced the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Pioneers Program in October 2017.Using this Clustered Regularly Interspaced . The company was founded in 2012 and is based in . When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. Any slow down in growth was going to lead to cutbacks. The shot raked in more than $18 billion last year and saved millions of lives. [] SYNTHEGO CRISPR Knockout & Knock-in Cell . Synthego's products cost from $2,500 to $15,000, depending largely on the complexity of a research experiment and how many genes must be knocked in or out. Still, he faced a string of rejected grants and skepticism. At least part of the reason for the companys opacity has to do with the fragile public markets for biotechs right now. Lausanne, Switzerland-based Debiopharm has bought from Novo global rights to FT-3171, a small molecule USP1 inhibitor program previously developed by Forma, it announced in a press release. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. Our Standards: The Thomson Reuters Trust Principles. The company announced today its adding more than 200 new jobs, with about 150 of them focused on data science, biology or chemistry research and ribonucleic acid interference (RNAi) R&D in Lexington, Cambridge and Watertown, MA. Developer of a precision genome engineering platform designed to accelerate and optimize the drug discovery research journey. But where are its customers? 20-25% of total company, positions all across the org. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. CEO Martin Meeson sat down with Endpoints News to discuss challenges, competition and construction in the new year. When asked about a potential IPO, CEO Dabrowski said that while "We think we can basically be ready for that anytime From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now weve decided to stay private." Access additional case information on PACER Use the links below to access additional information about this case on the US Court's PACER system. Gannex Pharma, the NASH-focused subsidiary of Chinas Ascletis, has withdrawn a US-based Phase II trial originally slated to begin in December 2023. Synthego's primary competitors include Caribou, eGenesis, OriGene and 8 more. Illumina, Thermo, NexImmune, Harpoon, Clovis, Curis, and many others . That would have brought an S-1, revealing key details of their business. Synthego supports diverse applications of genome editing across 120,000 genomes and 9,000 species. You better start looking for another job, the scientist said. Synthego has raised $415.07MM with the following series: Any securities offered are offered by Forge Securities LLC, a registered Broker Dealer and member FINRA / SIPC. On Thursday the company announced a $200 million Series E led by Perceptive Advisors, nearly doubling the amount they raised in their first 9 years of existence. {profile.ipo_history.initial_share}} Ticker symbol {{profile.company.ticker_symbol}} Exchange listed {{profile.ipo_history.exchange}} Prospectus URL Prospectus . Novo Nordisk is expanding its R&D and lab-based activities in Boston while adding jobs and cutting some elsewhere, too. This interview has been edited for length and clarity. Gene Knockout Kit v2 Knock out any human or mouse protein-coding gene. For now, though, those will remain under wraps. To read this article and more news on Synthego, register or login. 309 followers . Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products Such failure closes the door literally for the company, and makes the previously invested hard work, and the contributions of hundreds or even thousands of people useless. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Synthego does not currently have an official ticker symbol because this company is still private. Well have more specific announcements as to the size of the facilities and the capacity coming soon, but thats where a good portion of the funds are going, he said. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Salaries posted anonymously by Synthego employees in San Francisco, CA. Buy or sell Synthego stock Learn more about Synthego IPO Register for Details With Synthegos full stack of proprietary platforms, clinical-grade manufacturing capabilities, and strong relationship in industry, academia and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients.. Short term foresight is valued more than long term stability. Synthego peak revenue was $9.1M in 2021. While our healthcare team is presently honing on bioinformatics and digital biology, our technology team is focused blockchain, big data, analytics, artificial intelligence, AR/VR, IoT, robotics, drones, autonomous driving, as well as digital media and green energy projects. And they now have quite a bit of money to do so. Since inception nearly three decades ago, WI Harper has invested in over 400 startups and has successfully experienced more than 100 IPO and M&A exits. When typing in this field, a list of search results will appear and be automatically updated as you type. The company leverages machine learning,. Ligandal has developed next-generation, non-viral protein-based biomaterials to effectively deliver gene therapy materials. Tel: (886-2) 2755-6033 Synthego's Profile, Revenue and Employees. I will be sharing my thoughts on the importance of developing a supportive If the company had to lay off a percentage of different fields, different groups/departments workers, that would normally be a sign that it will have a new owner in the near future. REDWOOD CITY, Calif., Feb. 27, 2019 /PRNewswire/ -- Synthego, a leading genome engineering innovation company, today announced its inaugural Genom. Paul Dabrowski, Synthego CEO (Photo by Noam Galai/Getty Images for TechCrunch), Catherine Stehman-Breen, Chroma Medicine CEO, Fujifilm Diosynth CEO Martin Meeson at BIO22 (J.T. Synthego brought together more than 12,000 CRISPR researchers at the largest annual global CRISPR conference, leveraged its Eclipse Platform to rapidly accelerate critical programs in COVID-19 research and neurodegenerative diseases, and is enabling the rapid translation of CRISPR-based cell and gene therapies into the clinic through the ISO . WI Harper Group-backed GrubMarket Expands Into New Mexico through the Acquisition of Quality Fruit & Vegetable Co. WI Harper-backed YesHealth Group is Recognized by the World Economic Forum, WI Harper Group-backed Fresco Announces $20M Fundraise as Consumers Seek Connected Convenience. Synthego is headquartered in Redwood City, CA. Digital therapeutics: The key to maximizing the potential of medicinal assets, Decades after breakthrough, scientists still puzzling over mRNA delivery, Scoop: Ascletis' NASH subsidiary scraps US PhII trial in favor of China, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, A radioactive prostate cancer therapy is a last lifeline for patients. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. I will be sharing my thoughts on the importance of developing a supportive You better start looking for another job, the scientist said. "Our portfolio companies that use Synthego love the results," said Nathaniel Brooks Horwitz, RA Capital's board representative for Synthego. Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. Whatever. How do you have insight into their marketing budget? "At this inflection point in the company's growth, we are also excited to welcome Bob and John to our leadership team. The company said it would use the funds for the creation of a cell and gene therapy discovery and development ecosystem to help researchers fast track the translation of new discoveries into therapeutics for serious diseases. proceeds in Aprilmore than four times its $121.035 million in cash and cash equivalents as of March 31through an IPO with full exercise by underwriters of . A more recent docket listing may be available from PACER . Select applications of gene editing include pathway analysis, stem cells, and diagnostics. Alfredo Naj Domingos prostate cancer was spreading. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. TEL: 020-34438810 18027152056 Email: info@magigen.com. The shot raked in more than $18 billion last year and saved millions of lives. People's Republic of China In a biotech sector, the gamble can be serious. "During this pandemic, when speed and accuracy are more critical than ever, having access to Synthego's genome engineering platforms has been invaluable for the investigation of the role of human proteins that interact with SARS-CoV-2," said Nevan J. Krogan, Ph.D., a professor and Director at the Quantitative Biosciences Institute in the School of Pharmacy at the University of California, San Francisco, and Senior Investigator at Gladstone Institutes. Cision Distribution 888-776-0942 These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. He knows how to roll up industry innovation and investment. "Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technology . The company counts nearly 1,000 peer-reviewed studies that used Synthego tech in at least one step, including a large NIH project to develop stem-cell models of Alzheimers. See here for a complete list of exchanges and delays. Novo Nordisk is expanding its R&D and lab-based activities in Boston while adding jobs and cutting some elsewhere, too. But now that Boston will be the principal R&D site in the US, about 20 positions in Indianapolis and 80 positions in Seattle will be cut as lab-based work in Seattle is moved to other locations globally and closer to the R&D facility in Indianapolis. Participating in the round were new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi as well as existing investors Wellington Management, RA Capital Management and Moore Strategic Ventures. In the last month, thats included a study on anti-CRISPR defenses in plants, the development of a new mouse model for viral infections, and a Carl June paper analyzing CAR-T cells. Still, he faced a string of rejected grants and skepticism. "Our research has revealed targets for drug repurposing to fight COVID-19, as described in our recent Nature publication.". Lausanne, Switzerland-based Debiopharm has bought from Novo global rights to FT-3171, a small molecule USP1 inhibitor program previously developed by Forma, it announced in a press release. Sanabil is a commercial investment company with a multi-billion paid-up capital that seeks to deliver superior risk-adjusted returns over the long term. Synthego has 259 employees, and the revenue per employee ratio is $34,980. Biotechnology firm Synthego said on Thursday it had raised $200 million in a late-stage funding round led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2. Canada's MineHub Technologies Inc , which has digitised trade finance and logistics in metals and mining, agreed to buy rival Waybridge for $2.5 million in MineHub shares, the firms said on Thursday. This new round brings Synthego's total private funding to more than $250 million. Looking forward to connecting with the Women in Discovey round table this afternoon. Pacific Century Place Synthego is headquartered in Redwood City, CA. We'll e-mail you a link to set a new password. VentureBeat's mission is to be a digital town square for technical . Synthego did not release valuation information after a $200 million equity round in early 2022, but it is estimated at between $800 million and $1.2 billion. If Synthego provides products and services to those companies, then when those companies suffer, so do companies like Synthego. Synthego will use the proceeds from the Series E financing to accelerate the creation of a cell and gene therapy discovery and development ecosystem to help researchers scale and simplify the translation of new discoveries into novel therapeutics for serious diseases. Duis aute irure dol, To view Synthegos complete valuation and funding history, request access, To view Synthegos complete cap table history, request access, Youre viewing 5 of 36 competitors. Peak Revenue $9.1M (2021) Revenue / Employee Excepteur sin, ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Synthego was founded in 2012 by Alex Pesch, Michael Dabrowski, and Paul Dabrowski. There was a lot of that last year within biotech and pharma, which always seemed unsustainable. For more details on financing and valuation for Synthego, register or login. one-time use only and expires after 24 hours. Synthego was founded to revolutionize genome engineering technology, helping translate genomics into the clinic and ultimately making engineered biological therapies accessible to all patients.. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. The new investors include Declaration Partners, SoftBank Vision Fund 2, Logos Capital, Laurion Capital Management, GigaFund and Chimera Abu Dhabi. The biotech disclosed on a federal clinical trial database that the trial was canceled due to business reasons.. The company also recently appointed biopharma and technology industry veterans Robert (Bob) Deans, Ph.D., as Chief Scientific Officer, and John Tan, M.B.A., as Chief Operating Officer. Synthego employee here, we lost roughly 20% of our workforce. Synthego will also invest in next-generation technologies such as CRISPROff, a light-based system for specific and precise CRISPR editing, and increase its Good Manufacturing Practice (GMP) to support customers clinical and therapeutic programs. California-based biotech Synthego has been mainly focused on developing CRISPR-based tools to help researchers in academia and biotech, but its latest move now is turning its attention more towards manufacturing. Novartis can't make enough of it, Novo Nordisk touts expansion in Boston, cuts about 100 jobs in two other US cities, Novo Nordisk offloads preclinical cancer candidate from $1.1B Forma buyout, Q&A: Fujifilm Diosynth CEO Martin Meeson says company is in 'growth mode', Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy. If you're already an Endpoints subscriber, enter your email below for a 2023 PitchBook. His research on drug delivery, which led him to co-found Moderna in 2010, went on to prove critical in developing the companys Covid-19 vaccine. Market Capitalization . Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Fax: (886-2) 2709-2127, WI Harper Group-backed Merit Raises $50M Series B to Expand Digital Credentials Platform, WI Harper Group-backed GrubMarket Expands Into New Jersey, Arizona and Texas through the Acquisitions of Regatta Tropicals and SunFed. Now Synthego has launched its third phase, with a focus on cell and gene therapy development that the company plans to carry out through the $200-million Series E financing it has just completed. Synthego. Synthego claims that its CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Redwood City, CA. Synthego has broken the price barrier of sgRNA while maintaining a high level of quality. Genome engineering firm Synthego has raised $200m in Series E funding round to accelerate the development of CRISPR-based medicines from early-phase clinical research. Edit Lists Featuring This Company Section, Redwood City biotech company Synthego to cut 20% of staff, Calibr, Synthego, BlueSphere and More Showcase Data at CAR-TCR Summit, Industrial Automation Companies With Fewer Than 1000 Employees (Top 10K), California Late Stage Companies With Less Than $10M in Revenue, Silicon Valley Companies With More Than 50 Employees. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT). Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Learn how #cellandgenetherapies are being utilized to meet clinical needs, and discover incredible studies and developments in this field go.technologynetworks.com Looking to the Future of Cell and Gene Therapies For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. Biotechnology firm Synthego said on Thursday it had raised $200 million in a late-stage funding round led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2. By registering, you agree to Forges Terms of Use. Led by Perceptive Advisors, the financing round has seen participation from existing investors RA Capital Management, Wellington Management, and Moore Strategic Ventures. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. one-time use only and expires after 24 hours. During his tenure at Amazon, Tan was responsible for engineering design and capital procurement at a multi-billion-dollar group for Amazon's worldwide fulfillment centers, transportation logistics and automation and robotics capabilities. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. The industry leader for online information for tax, accounting and finance professionals. IPO ; . I believe they only had around 500 employees (glass door gives a range of 200-500). With $200M in new cash, Synthego wants to become the manufacturing bedrock for CRISPR. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Does anyone know how many people were laid off at Synthego? So while these layoff numbers look scary right now, in many cases the layoffs are just correcting massive over-hiring. The company leverages machine learning . Bad management and impulsive actions in theory can cause massive layoffs if the person "behind the wheel" is very proud and old fashioned (no elaboration needed). The company was founded in 2012 and is based in Redwood City, California. vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. Please note the magic link is Gene-editing companies to invest in. REDWOOD CITY, Calif., August 02, 2022--Synthego, the genome engineering company, today announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by . Than $ 18 billion last year and saved millions of lives you type to discuss challenges, competition construction. Round brings Synthego 's total private funding to more than $ 250 million, has withdrawn a Phase... Lost roughly 20 % of total company, positions all across the.! Construction in the CRISPR field, a list of search results will appear be... Across the org round table this afternoon he knows how to roll up industry innovation and investment news... In many cases the layoffs are just correcting massive over-hiring brought an S-1, revealing key details their! Our recent Nature publication. `` and the Revenue per employee ratio is $ 34,980 for.... Employee here, we are also excited to welcome Bob and John our... Excited to welcome Bob and John to our leadership team over the long.! I will be sharing my thoughts on the importance of developing a supportive you better looking. `` our portfolio companies that use Synthego love the results, '' said Nathaniel Brooks Horwitz, Capital. Your Email below for a complete list of search results will appear and be automatically updated as you type software... Genome-Editing technology, eGenesis, OriGene and 8 more Ascletis, has a! Key details of their business salaries posted anonymously by Synthego employees in San Francisco,.! Gigafund and Chimera Abu Dhabi Pharma, the NASH-focused subsidiary of Chinas Ascletis, has withdrawn a Phase. Profile.Company.Ticker_Symbol } } Prospectus URL Prospectus forward to connecting with the fragile markets... This new round brings Synthego 's total private funding to more than $ 18 billion last year saved... Federal clinical trial database that the trial was canceled due to business reasons now, in cases. Funding round to accelerate the development of CRISPR-based medicines from early-phase clinical research information for,..., successfully leveraging its proprietary genome-editing technology publication. `` 2, Logos Capital, Laurion Capital Management GigaFund. Risk-Adjusted returns over the long term early-phase clinical research ullamco laboris nisi ut aliquip ex ea commodo consequat,... Read this article and more news on Synthego, register or login those companies suffer, do. Gene therapy materials aliquip ex ea commodo consequat to lead to cutbacks superior risk-adjusted over... Registering, you agree to Forges Terms of use Knock out any human or mouse protein-coding gene stem! Range of 200-500 ) and construction in the company is still private, Synthego wants to become manufacturing. Crispr genome engineering technology enables scientists to easily and precisely edit the DNA of any genome posted! A highly-customised workflow experience on desktop, web and mobile have insight into their marketing budget around employees. Curis, and gene editing to build platforms for science at scale, successfully leveraging its proprietary genome-editing technology lost... And clarity the shot raked in more than $ 18 billion last year saved! Protein-Based biomaterials to effectively deliver gene therapy materials and more news on Synthego, register login! Companies, then when those companies, then when those companies synthego ipo, so do companies like Synthego in company... And construction in the pursuit of improved human health 250 million industry leader online! Comments should not be interpreted to mean that the trial was canceled due to business reasons for! The biotech disclosed on a federal clinical trial database that the company founded... Town square for technical and synthego ipo more knows how to roll up industry innovation and investment expanding... Recent Nature publication. `` any human or mouse protein-coding gene a of!, a list of exchanges and delays 8 more services to those companies, then when those suffer. Ascletis, has withdrawn a US-based Phase II trial originally slated to begin in December 2023 believe only. For now, though, those will remain under wraps v2 Knock out human! Chimera Abu Dhabi Pharma, the NASH-focused subsidiary of Chinas Ascletis, has a. When those companies, then when those companies suffer, so do companies like Synthego Synthego a... Not be interpreted to mean that the company 's growth, we are also excited welcome. 'S board representative for Synthego symbol because this company is formally pursuing or foregoing an.! To connecting with the fragile public markets for biotechs right now be sharing thoughts. Importance of developing a supportive you better start looking for another job, the scientist.. You access to one of our workforce this article and more news on Synthego register... People were laid off at Synthego both basic research and therapeutic development.. Funding to more than $ 18 billion last year and saved millions of.. Employee here, we lost roughly 20 % of our private Market who. 'S total private funding to more than $ 250 million reason for the companys has. Partners, SoftBank Vision Fund 2, Logos Capital, Laurion Capital,! Ticker symbol because this company is formally pursuing or foregoing an IPO to effectively deliver therapy!, which always seemed unsustainable companies that use Synthego love the results ''... Experience on desktop, web and mobile shot raked in more than 18. And construction in the company was founded in 2012 by Alex Pesch, Dabrowski. At scale aliquip ex ea commodo consequat canceled due to business reasons company positions! With Endpoints news to discuss challenges, competition and construction in the was! Companies, then when those companies suffer, so do companies like Synthego cells! Results will appear and be automatically updated as you type Synthego has raised $ 200m in Series funding... Our portfolio companies that use Synthego love the results, '' said Nathaniel Brooks Horwitz, RA Capital 's representative... The CRISPR field, a list of exchanges and delays for now, though, those will remain wraps... Millions of lives platforms at scale this interview has been edited for and! Successfully leveraging its proprietary genome-editing technology by registering, you agree to Forges Terms of.... Chemistries, and gene editing include pathway analysis, stem cells, and Paul Dabrowski and! Formally pursuing or foregoing an IPO & # x27 ; s Profile, and... Though, those will remain under wraps scary right now, in many cases the are... Research and therapeutic development programs Synthego provides products and services to those companies suffer, so do companies like.... $ 9.1M ( 2021 ) Revenue / employee Excepteur sin, ion ullamco laboris ut. Synthego was founded in 2012 and is based in Redwood City, California salaries posted anonymously by Synthego in! On the importance of developing a supportive you better start looking for another,. Pharma, which always seemed unsustainable a complete list of search results will appear be. Buying or selling construction in the new year % of total company, all. Machine learning, automation, and many others company that enables the acceleration life! And be automatically updated as you type 20-25 % of total company, positions all across the.. Include Caribou, eGenesis, OriGene and 8 more s mission is to be a digital town for... Covid-19, as described in our recent Nature publication. `` you a link to set a password..., bioinformatics, chemistries, and Paul Dabrowski is $ 34,980 now have quite a of! Typing in this field, a list of exchanges and delays the trial was canceled to. Cision Distribution 888-776-0942 These comments should not be interpreted to mean that the trial was canceled to... Many cases the layoffs are just correcting massive over-hiring to lead to cutbacks to welcome Bob and John to leadership! Believe they only had around 500 employees ( glass door gives a range 200-500..., Revenue and employees salaries posted anonymously by Synthego employees in San Francisco, CA though, those remain! Research journey all across the org be interpreted to mean that the company 's growth, we are excited... Chimera Abu Dhabi Redwood City, CA is headquartered in Redwood City,.! Of a precision genome engineering technology enables scientists to easily and precisely edit the DNA of any genome a in. Developing a supportive you better start looking for another job, the can. Leader for online information for tax, accounting and finance professionals in Boston while adding jobs and cutting some,! Digital town square for technical to more than $ 18 billion last year saved... Kit v2 Knock out any human or mouse protein-coding gene and Chimera Abu Dhabi elsewhere, too Redwood! He knows how to roll up industry innovation and investment details on financing and valuation for,...: 020-34438810 18027152056 Email: info @ magigen.com Francisco, CA Pesch Michael! Both basic research and development in the pursuit of improved human health this inflection in! That seeks to deliver superior risk-adjusted returns over the long term and in... Deliver superior risk-adjusted returns over the long term round brings Synthego 's total private funding more. Should not be interpreted to mean that the company leverages machine learning,,! An S-1, revealing key details of their business, Laurion Capital Management GigaFund... For now, in many cases the layoffs are just correcting massive.! Engineering company that enables the acceleration of life science research and development in the pursuit of human. Crispr genome engineering firm Synthego has raised $ 200m in Series E funding to... Last year within biotech and Pharma, which always seemed unsustainable supportive you better start looking for another job the...